Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Andrea Negro, Angela Koverech & Paolo Martelletti. (2018) Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. Journal of Pain Research 11, pages 515-526.
Read now
Read now
Amanda E. Macone & Michael D. Perloff. (2017) Triptans and migraine: advances in use, administration, formulation, and development. Expert Opinion on Pharmacotherapy 18:4, pages 387-397.
Read now
Read now
Piero Barbanti, C. Aurilia, G. Egeo, L. Fofi & R. Palmirotta. (2017) Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development. Expert Opinion on Investigational Drugs 26:3, pages 269-277.
Read now
Read now
Fernando de Andrés, Luana Lionetto, Martina Curto, Matilde Capi, Fabiola Cipolla, Andrea Negro & Paolo Martelletti. (2016) Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. Expert Opinion on Drug Metabolism & Toxicology 12:9, pages 1011-1020.
Read now
Read now
Roger Cady. (2015) The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine. Expert Opinion on Pharmacotherapy 16:13, pages 2039-2051.
Read now
Read now
Paolo Martelletti. (2015) Cluster headache management and beyond. Expert Opinion on Pharmacotherapy 16:10, pages 1411-1415.
Read now
Read now
Paolo Martelletti. (2015) The therapeutic armamentarium in migraine is quite elderly. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 175-177.
Read now
Read now
Flavia Napoletano, Luana Lionetto & Paolo Martelletti. (2014) Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opinion on Pharmacotherapy 15:3, pages 303-305.
Read now
Read now
Stephen D Silberstein & Dawn A Marcus. (2013)
Sumatriptan: treatment across the full spectrum of migraine. Expert Opinion on Pharmacotherapy 14:12, pages 1659-1667.
Read now
Read now
Articles from other publishers (17)
Guanglu Li, Shaojie Duan, Tiantian Zhu, Zhiying Ren, Hui Xia, Ziyao Wang, Lei Liu & Zunjing Liu. (2023) Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. The Journal of Headache and Pain 24:1.
Crossref
Crossref
Kuan-Po Peng & Mark J. Burish. (2023) Management of cluster headache: Treatments and their mechanisms. Cephalalgia 43:8.
Crossref
Crossref
Anvay Ukidve, Kelvin B. Rembert, Ragaleena Vanipenta, Patrick Dorion, Pierre Lafarguette, Timothy McCoy, Atul Saluja, Raj Suryanarayanan & Sanket Patke. (2023) Succinate Buffer in Biologics Products: Real-world Formulation Considerations, Processing Risks and Mitigation Strategies. Journal of Pharmaceutical Sciences 112:1, pages 138-147.
Crossref
Crossref
Diéssica P. Dalenogare, Maria C. Theisen, Diulle S. Peres, Maria F.P. Fialho, Nathaly Andrighetto, Laura Barros, Lorenzo Landini, Mustafa Titiz, Francesco De Logu, Sara M. Oliveira, Pierangelo Geppetti, Romina Nassini & Gabriela Trevisan. (2022) Transient receptor potential ankyrin 1 mediates headache-related cephalic allodynia in a mouse model of relapsing–remitting multiple sclerosis. Pain 163:7, pages 1346-1355.
Crossref
Crossref
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine
639
881
.
Diéssica Padilha Dalenogare, Camila Ritter, Fernando Roberto Antunes Bellinaso, Sabrina Qader Kudsi, Gabriele Cheiran Pereira, Maria Fernanda Pessano Fialho, Débora Denardin Lückemeyer, Caren Tatiane de David Antoniazzi, Lorenzo Landini, Juliano Ferreira, Guilherme Vargas Bochi, Sara Marchesan Oliveira, Francesco De Logu, Romina Nassini, Pierangelo Geppetti & Gabriela Trevisan. (2021) Periorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation. Pharmaceuticals 14:8, pages 831.
Crossref
Crossref
Richard B. Lipton, Sagar Munjal, Elimor Brand-Schieber & Alan M. Rapoport. (2019) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. CNS Drugs 33:4, pages 375-382.
Crossref
Crossref
Stephen Landy, Sagar Munjal, Elimor Brand-Schieber & Alan M. Rapoport. (2018) Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. The Journal of Headache and Pain 19:1.
Crossref
Crossref
Magdalena Paczkowska, Mikołaj Mizera, Kinga Sałat, Anna Furgała, Piotr Popik, Justyna Knapik-Kowalczuk, Anna Krause, Daria Szymanowska-Powałowska, Zbigniew Fojud, Maciej Kozak, Marian Paluch & Judyta Cielecka-Piontek. (2018) Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins. Scientific Reports 8:1.
Crossref
Crossref
Richard B. Lipton, Sagar Munjal, Elimor Brand‐Schieber & Alan M. Rapoport. (2018) DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study. Headache: The Journal of Head and Face Pain 58:5, pages 676-687.
Crossref
Crossref
Sagar Munjal, Elimor Brand-Schieber, Kent Allenby, Egilius L.H. Spierings, Roger K. Cady & Alan M. Rapoport. (2017) A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Roger K. Cady, Sagar Munjal, Ryan J. Cady, Heather R. Manley & Elimor Brand-Schieber. (2017) Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Donald J Kellerman, Mahmoud Ameri & Stewart J Tepper. (2017) Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray. Pain Management 7:6, pages 559-567.
Crossref
Crossref
Richard B. Lipton, James S. McGinley, Kenneth J. Shulman, R.J. Wirth & Dawn C. Buse. (2017) Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO. Headache: The Journal of Head and Face Pain 57:10, pages 1570-1582.
Crossref
Crossref
Mitra Jelvehgari, Hadi Valizadeh, Sanam Ziapour, Mahdieh Rahmani, Seyed Hassan Montazam & Saieede Soltani. (2016) Comparative Study of Different Combinational Mucoadhesive Formulations of Sumatriptan-Metoclopramide. Advanced Pharmaceutical Bulletin 6:1, pages 119-130.
Crossref
Crossref
Sagar S. Rane & Derek Moe. 2015. Oral Mucosal Drug Delivery and Therapy. Oral Mucosal Drug Delivery and Therapy
169
205
.
Alisson Oshiro, Deyse C. da Silva, Joyce C. de Mello, Vivian W. R. de Moraes, Leide P. Cavalcanti, Margareth K. K. D. Franco, Melissa I. Alkschbirs, Leonardo F. Fraceto, Fabiano Yokaichiya, Tiago Rodrigues & Daniele R. de Araujo. (2014) Pluronics F-127/L-81 Binary Hydrogels as Drug-Delivery Systems: Influence of Physicochemical Aspects on Release Kinetics and Cytotoxicity. Langmuir 30:45, pages 13689-13698.
Crossref
Crossref